All In Biotech

Drug Trial Radar · NCT02476006

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

998

Actual

Start

Jun 23, 2015

Primary completion

Apr 12, 2019

Study completion Apr 12, 2019

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population. Secondary Objectives: To document the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels as well as non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels after 12 weeks of treatment. To document participant's acceptability of self-injection (Self Injection Assessment Questionnaire, SIAQ).

Conditions

  • Hypercholesterolemia

Interventions

  • ALIROCUMAB SAR236553 (REGN727)Drug

    Pharmaceutical form:solution Route of administration: subcutaneous

  • placebo (for injection training only)Drug

    Pharmaceutical form:solution Route of administration: subcutaneous

  • ezetimibeDrug

    Pharmaceutical form:capsule Route of administration: oral

  • atorvastatinDrug

    Pharmaceutical form:tablet Route of administration: oral

  • rosuvastatinDrug

    Pharmaceutical form:tablet Route of administration: oral

  • simvastatinDrug

    Pharmaceutical form:tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)

Locations

153 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 040001

    Graz, Austria

  • Investigational Site Number 040008

    Innsbruck, Austria

  • Investigational Site Number 040005

    Linz, Austria

  • Investigational Site Number 040006

    Linz, Austria

  • Investigational Site Number 040003

    Vienna, Austria

  • Investigational Site Number 040002

    Vienna, Austria

  • Investigational Site Number 040004

    Vienna, Austria

  • Investigational Site Number 040007

    Vienna, Austria

  • Investigational Site Number 040010

    Vienna, Austria

  • Investigational Site Number 056005

    Aalst, Belgium

  • Investigational Site Number 056018

    Antwerp, Belgium

  • Investigational Site Number 056008

    Arlon, Belgium

  • Investigational Site Number 056013

    Bruges, Belgium

  • Investigational Site Number 056010

    Brussels, Belgium

  • Investigational Site Number 056003

    Brussels, Belgium

  • Investigational Site Number 056006

    Charleroi, Belgium

  • Investigational Site Number 056007

    Edegem, Belgium

  • Investigational Site Number 056019

    Genk, Belgium

  • Investigational Site Number 056001

    Ghent, Belgium

  • Investigational Site Number 056017

    Ghent, Belgium

  • Investigational Site Number 056002

    Haine-Saint-Paul, Belgium

  • Investigational Site Number 056015

    Kortrijk, Belgium

  • Investigational Site Number 056009

    La Louvière, Belgium

  • Investigational Site Number 056004

    Leuven, Belgium

  • Investigational Site Number 056014

    Liège, Belgium

  • Investigational Site Number 056011

    Overpelt, Belgium

  • Investigational Site Number 056016

    Roeselare, Belgium

  • Investigational Site Number 124018

    Calgary, Canada

  • Investigational Site Number 124015

    Cambridge, Canada

  • Investigational Site Number 124002

    Chicoutimi, Canada

  • Investigational Site Number 124027

    Coquitlam, Canada

  • Investigational Site Number 124025

    Edmonton, Canada

  • Investigational Site Number 124017

    Halifax, Canada

  • Investigational Site Number 124013

    Hamilton, Canada

  • Investigational Site Number 124008

    London, Canada

  • Investigational Site Number 124026

    Maple Ridge, Canada

  • Investigational Site Number 124020

    Montreal, Canada

  • Investigational Site Number 124022

    Montreal, Canada

  • Investigational Site Number 124032

    Mount Pearl, Canada

  • Investigational Site Number 124005

    Ottawa, Canada

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.